Black Rock Inc. Seagen Inc. Transaction History

Black Rock Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$191.51 - $216.16 $1.9 Million - $2.15 Million	9,926 Added 0.08%	12,051,745 $2.56 Billion
Q2 2023 Aug 11, 2023	BUY	$187.64 - $206.25 $160 Million - $175 Million	850,697 Added 7.6%	12,041,819 $2.32 Billion
Q1 2023 May 12, 2023	SELL	$127.59 - $203.08 $85.6 Million - $136 Million	-670,912 Reduced 5.66%	11,191,122 $2.27 Billion
Q4 2022 Feb 13, 2023	BUY	$117.37 - $139.17 $4.13 Million - $4.9 Million	35,212 Added 0.3%	11,862,034 $1.52 Billion
Q3 2022 Nov 14, 2022	BUY	$135.27 - $180.11 $53.4 Million - $71.1 Million	394,562 Added 3.45%	11,826,822 $1.62 Billion

Q2 2022 Aug 12, 2022	SELL	$108.81 - $179.33 $247 Million - $407 Million	-2,272,095 Reduced 16.58%	11,432,260 $2.02 Billion
Q1 2022 May 12, 2022	BUY	$119.61 - $157.85 $43.4 Million - $57.2 Million	362,602 Added 2.72%	13,704,355 $1.97 Billion
Q4 2021 Feb 10, 2022	BUY	$142.57 - $190.86 $156 Million - $208 Million	1,090,927 Added 8.9%	13,341,753 $2.06 Billion
Q3 2021 Nov 09, 2021	BUY	$142.45 - $169.82 $32.5 Million - $38.7 Million	227,910 Added 1.9%	12,250,826 $2.08 Billion
Q2 2021 Aug 11, 2021	BUY	$135.08 - $161.1 $1.62 Billion - $1.94 Billion	12,022,916 New	12,022,916 $1.9 Billion

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.